Statistics

Total Visits

Views
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations34

File Visits

Downloads
1060.pdf21

Select a period of time:

Number of views in the range

Views
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations34

Number of downloads in the range

Downloads
1060.pdf21

Views

Views
October 20253
November 20253
December 20252
January 20266
February 20260
March 202616
April 20264
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • October 2025
    0
  • November 2025
    2
  • December 2025
    1
  • January 2026
    4
  • February 2026
    0
  • March 2026
    6
  • April 2026
    8
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
United States15
Spain4
Argentina3
Netherlands2
Benin1
Brazil1
Colombia1
Germany1
France1
Greece1
 

Top countries by downloads

Downloads
United States9
Netherlands2
Argentina1
 

Top cities views

Views
San Jose6
Madrid4
Amsterdam1
Ashburn1
Athens1
Barranquilla1
Buenos Aires1
Elburg1
Hamburg1
Los Angeles1
 

Top cities by downloads

Downloads
Amsterdam2
Los Angeles2
Ashburn1